Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
The final trial results showed a continued, ongoing survival benefit with nivolumab plus ipilimumab and with nivolumab monotherapy, as compared with ipilimumab monotherapy, in patients with advanced melanoma. (Funded by Bristol Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).
Authors
- John R. Walker (ORCID: https://orcid.org/0000-0002-5349-1689)
- Marcus O. Butler (ORCID: https://orcid.org/0000-0002-9840-7057)
- Michael Andrew Postow (ORCID: https://orcid.org/0000-0002-3367-7961)
- John B.A.G. Haanen (ORCID: https://orcid.org/0000-0001-5884-7704)
- John Wagstaff (ORCID: https://orcid.org/0000-0002-1140-5981)
- Michele Maio (ORCID: https://orcid.org/0000-0002-0323-6321)
- Patrick Schöffski (ORCID: https://orcid.org/0000-0001-5980-030X)
- Massimo Guidoboni (ORCID: https://orcid.org/0000-0001-7703-790X)
- Célèste Lebbé (ORCID: https://orcid.org/0000-0002-5854-7290)
- C. Lance Cowey (ORCID: https://orcid.org/0000-0001-8597-8486)
- Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
- Theresa Michelle Medina (ORCID: https://orcid.org/0000-0003-0579-4121)
- Ayman Hamdy Nassar (ORCID: https://orcid.org/0000-0001-7421-3496)
- Vanna Chiarion‐Sileni (ORCID: https://orcid.org/0000-0001-9191-9124)
- Melanie Pe Benito
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Caroline Gaudy‐Marqueste (ORCID: https://orcid.org/0000-0001-6955-5117)
- Jedd D. Wolchok (ORCID: https://orcid.org/0000-0001-6718-2222)
- Andrew Hill (ORCID: https://orcid.org/0000-0001-8672-6379)
- Iván Márquez‐Rodas (ORCID: https://orcid.org/0000-0002-2476-668X)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Paola Queirolo (ORCID: https://orcid.org/0000-0002-9917-6633)
- Piotr Rutkowski (ORCID: https://orcid.org/0000-0002-8920-5429)
- James Larkin (ORCID: https://orcid.org/0000-0001-5569-9523)
- Margarita Askelson (ORCID: https://orcid.org/0000-0001-9133-7693)
- Matteo Salvatore Carlino (ORCID: https://orcid.org/0000-0002-7861-4104)
- Corey Ritchings (ORCID: https://orcid.org/0000-0002-9240-9211)
- F. Stephen Hodi (ORCID: https://orcid.org/0000-0001-6825-091X)
- Reinhard Dummer (ORCID: https://orcid.org/0000-0002-2279-6906)
- Wenjia Wang (ORCID: https://orcid.org/0000-0003-0336-9412)
- Christopher D. Lao
- Shahneen Sandhu
Institutions
- Cornell University (US)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1056/nejmoa2407417
- Citations
- 378
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 106.80
Funders
- Bristol-Myers Squibb
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Ono Pharmaceutical
- National Cancer Institute